Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75943
UPID:
RAD17_HUMAN
Alternative names:
RF-C/activator 1 homolog
Alternative UPACC:
O75943; A8K8X2; D3DWA5; O75714; Q7Z3S4; Q9UNK7; Q9UNR7; Q9UNR8; Q9UPF5
Background:
Cell cycle checkpoint protein RAD17, also known as RF-C/activator 1 homolog, plays a pivotal role in cell growth, chromosomal stability, and DNA damage response. It exhibits a weak ATPase activity essential for chromatin binding, facilitating the recruitment of RAD1-RAD9-HUS1 complex and RHNO1, crucial for CHEK1 activation. RAD17 may also act as a DNA replication progress sensor and participate in homologous recombination.
Therapeutic significance:
Understanding the role of Cell cycle checkpoint protein RAD17 could open doors to potential therapeutic strategies.